Antimicrobial Susceptibility - AFB/Mycobacterium tuberculosis Primary Panel
Also known as: MA AFB
Use
This test identifies the susceptibility of clinically significant isolates of Mycobacterium tuberculosis complex (MTBC) and other mycobacteria to first-line drugs. It helps determine appropriate antibiotic treatment by screening for drug resistance. The primary panel assesses the susceptibility of isolates to first-line drugs such as Ethambutol, Isoniazid, and Rifampin, providing crucial information for the management of tuberculosis.
Special Instructions
Not provided.
Limitations
The procedure screens M. tuberculosis complex isolates for drug resistance using single critical concentrations defined by the United States Public Health Service. Hence, specific quantitative MIC values are not provided, potentially limiting detailed assessment of resistance levels. Mixed isolates or nonviable organisms will not be processed. M. tuberculosis complex isolates on agar plates are also unacceptable. Results should be considered in conjunction with clinical presentation, and the lack of serial dilution could impact nuanced insight into resistance patterns.
New York Approved
Methodology
Culture-based
Biomarkers
Ethambutol
AnalyteIsoniazid
AnalyteRifampin
Analyte
Result Turnaround Time
0 days
Related Documents
For more information, please review the documents below
Specimen
Cultured Cells
Volume
Not provided
Minimum Volume
Not provided
Container
Sealed container
Collection Instructions
Transport pure isolate on solid or liquid media. Place each isolate in its own sealed bag.
Storage Instructions
Submit M. tuberculosis complex isolates according to Infectious Substance, Category A shipping guidelines.
Causes for Rejection
Mixed isolates or nonviable organisms. M. tuberculosis complex isolates submitted on an agar plate.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 2 weeks |
| Refrigerated | 2 weeks |
| Frozen | unacceptable |
Other tests from different labs that may be relevant